Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07143110

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Neoplasms Lung Diseases Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–130 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Calgary, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with lung cancer between January 1, 2018 and end of the Selection Period.
  • Patient is 18 years of age or older on diagnosis date.
  • Patient has at least 12 months of health insurance coverage prior to the diagnosis date.

Exclusion criteria

  • Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
  • Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
  • Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
  • Non-Ontario or non-Alberta resident on diagnosis date.

Treatment and study plan

Primary outcomes

  1. Treatment patterns

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Incidence and prevalence

    Time frame: Through study completion, an average of 1 year

  2. Baseline demographic and clinical characteristics

    Time frame: Through study completion, an average of 1 year

  3. Overall survival

    Time frame: Through study completion, an average of 6 months

  4. Time to/on therapy

    Time frame: Through study completion, an average of 6 months

  5. Attrition rates

    Time frame: Through study completion, an average of 1 year

  6. Healthcare resource utilization (HCRU)

    Time frame: Through study completion, an average of 1 year

  7. Direct healthcare costs

    Time frame: Through study completion, an average of 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

AstraZeneca Clinical Study Information Center

CONTACT

[email protected]

1-877-240-9479

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: LUNG-ROLL

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Aug 27, 2025
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.